Research at Naresuan University compares the value of 2 types of nasal sprays for allergies.

A Health Economic Evaluation study from Naresuan University published in Pharmacy Practice 2026 examined the health economics value of two nasal sprays, Intranasal Olopatadine (INOP) and Fluticasone Furoate Nasal Spray (FFNS), for the treatment of allergic rhinitis, using 52 patient data in combination with a 1-year health economics model, found that Olopatadine averaged a cost of THB 10,271.90 per year, giving a result of 0.74 QALYs, while Fluticasone Furoate averaged a cost of 9,330.08.THB per year yields 0.83 QALYs under the base-case model, so the Olopatadine approach is dominated at a higher cost, but the results are lower. However, the authors emphasize that it should be interpreted cautiously because the sample and severity of the disease in each group of patients are different. The authors include Chanida Chantim, Prayuth Poowaruttanawiwit, and Rattharada Suriyapak, affiliated with Naresuan University, Thailand, published in the journal Pharmacy Practice. 2026; 24 (4): 3800.

# Health Economics # HealthEconomics # Pharmacoeconomics # AllergicRhinitis # NaresuanUniversity